Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Melanoma Updates: Survival Outcomes, Treatment Advances, and Surveillance Imaging
Description
The talk reviewed current melanoma epidemiology, treatment advances, and surveillance. Melanoma incidence remains high, with large numbers of invasive and in situ cases, but mortality has fallen substantially, largely due to immune checkpoint inhibitors. The speaker emphasized converting relative risk into absolute risk for patient counseling and noted that incidence has generally risen and then leveled off. A major focus was long-term outcomes from a 10-year trial of nivolumab plus ipilimumab versus either drug alone in unresectable stage III/IV melanoma: combination therapy produced the best overall and melanoma-specific survival, with about 43% alive at 10 years and especially strong durable benefit in patients who reached 3 years without progression. The combination remains the most effective option, including for brain metastases, but toxicity is significant and about a third discontinue treatment. Outcomes were better in BRAF-mutant disease than in BRAF-wild-type disease, and if patients make it to year 3, their chance of reaching year 10 is very high. In contrast, a retrospective study in acral melanoma showed only modest responses to checkpoint inhibitors, with short progression-free and overall survival, highlighting this subtype’s treatment resistance and need for more research. Finally, a Swedish randomized trial found that intensive routine surveillance imaging after surgery for high-risk melanoma did not improve survival compared with standard follow-up, supporting more conservative imaging strategies and helping address patient anxiety about frequent scans.
View moreConclusions
- Modern immune checkpoint therapy has transformed advanced melanoma outcomes, with nivolumab plus ipilimumab producing the best long-term survival but also substantial toxicity.
- For patients with metastatic melanoma who remain disease-free for three years after treatment, the likelihood of surviving to ten years is extremely high.
- Melanoma survival is markedly better now than in the pre-immunotherapy era, although a substantial fraction of patients still do not respond and resistant disease remains a major unmet need.
- Patients with BRAF-mutant melanoma may have somewhat better outcomes, but the combination immunotherapy benefit remains strong across molecular subgroups.
- Acral melanoma responds much less well to dual checkpoint blockade than cutaneous melanoma, confirming it as a biologically distinct and more treatment-resistant disease.
- Ethnicity and disease burden appear to influence acral melanoma outcomes, but the poor results are not explained by access alone.
- Because acral melanoma is rare and underrepresented in trials, more tailored therapies and deeper molecular study are needed.
- Routine intensive whole-body imaging after high-risk melanoma surgery does not appear to improve overall survival compared with physical examination-based follow-up.
- These imaging data support moving toward less intensive surveillance and reducing unnecessary scans that add cost and anxiety without clear benefit.
- CA Cancer J Clin. 2026;e7004.
- N Engl J Med 2025;392:11-22.
- Br J Dermatol 2025; 192:316-326.
- Br J Dermatol 2025; 192:316–326.
- Lancet Oncol 2025; 26: 1501–10.